UnknownNot Applicable

Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage

United States42 participantsStarted 2018-05-01

Plain-language summary

This study will provide novel information to the literature base for the pathophysiology of aneurysmal subarachnoid hemorrhage. The association of breakdown products in the serum of aSAH patients were reported in a very small case series of 3 patients, as mentioned above. However, while their results are intriguing and encouraging, our study will provide more definitive information about the GC in aSAH. If there is a positive correlation, the results of this study will guide future investigations into new therapies for this devastating disease such as MMP inhibition with doxycycline.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * • Age 18 years of age and older * Cerebral aneurysm on CT-angio Exclusion Criteria: * • comfort care only orders, * the absence of an aneurysm on CT-angiography, * onset of aneurysm rupture \> 24 hours, * and inability to obtain informed consent from patient or family pregnant women

What they're measuring

Syndecan-1 and heparin sulfate

Timeframe: day 0 through day 13

Trial details

NCT IDNCT03706768

SponsorUniversity of Virginia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-05-01

Contact for this trial

Marcia E Birk

434-924-2283 meb2w@virginia.edu

View on ClinicalTrials.gov More Aneurysmal Subarachnoid Hemorrhage trials